These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 33628620)

  • 1. Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer.
    Petriv N; Neubert L; Vatashchuk M; Timrott K; Suo H; Hochnadel I; Huber R; Petzold C; Hrushchenko A; Yatsenko AS; Shcherbata HR; Wedemeyer H; Lichtinghagen R; Falfushynska H; Lushchak V; Manns MP; Bantel H; Semchyshyn H; Yevsa T
    Oncoimmunology; 2021 Feb; 10(1):1874159. PubMed ID: 33628620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of hub genes and key pathways of dietary advanced glycation end products‑induced non‑alcoholic fatty liver disease by bioinformatics analysis and animal experiments.
    Wang J; Liu H; Xie G; Cai W; Xu J
    Mol Med Rep; 2020 Feb; 21(2):685-694. PubMed ID: 31974594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Takino J; Nagamine K; Hori T; Sakasai-Sakai A; Takeuchi M
    World J Hepatol; 2015 Oct; 7(23):2459-69. PubMed ID: 26483867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.
    Fernando DH; Forbes JM; Angus PW; Herath CB
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
    de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
    J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of Intracellular TAGE and the TAGE-RAGE-ROS Axis in the Onset and Progression of NAFLD/NASH.
    Sakasai-Sakai A; Takeda K; Takeuchi M
    Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro.
    Ji J; Feng M; Huang Y; Niu X
    Bioengineered; 2022 Mar; 13(3):5091-5102. PubMed ID: 35164657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.
    Leung C; Herath CB; Jia Z; Andrikopoulos S; Brown BE; Davies MJ; Rivera LR; Furness JB; Forbes JM; Angus PW
    World J Gastroenterol; 2016 Sep; 22(35):8026-40. PubMed ID: 27672297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAGE deficiency does not affect non-alcoholic steatohepatitis and atherosclerosis in Western type diet-fed Ldlr
    Bijnen M; Beelen N; Wetzels S; Gaar JV; Vroomen M; Wijnands E; Scheijen JL; van de Waarenburg MPH; Gijbels MJ; Cleutjens JP; Biessen EAL; Stehouwer CDA; Schalkwijk CG; Wouters K
    Sci Rep; 2018 Oct; 8(1):15256. PubMed ID: 30323247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults.
    Palma-Duran SA; Kontogianni MD; Vlassopoulos A; Zhao S; Margariti A; Georgoulis M; Papatheodoridis G; Combet E
    Metabolism; 2018 Jun; 83():120-127. PubMed ID: 29409822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.